This study offers novel insights into the impact of CD44/HAS1/MMP9 on ccRCC tumorigenesis and invasion, with potential implications for early metastasis prediction and the development of more effective treatment strategies. The gene discussed is HAS1; the disease is nonpapillary renal cell carcinoma.